An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life
Dengue is caused by a mosquito-transmitted flavivirus. The disease is now endemic to many tropical and subtropical regions, manifesting as approximately 96 million symptomatic cases of dengue each year. Clinical trials have shown TAK-003 (Qdenga®), a live attenuated dengue tetravalent vaccine, to be...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Taylor & Francis Group
2023-08-01
|
| 叢編: | Human Vaccines & Immunotherapeutics |
| 主題: | |
| 在線閱讀: | http://dx.doi.org/10.1080/21645515.2023.2254964 |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|